... a collaboration with Inflamax Research who has tremendous amount of experience and strong track record with successful Environmental Exposure Chamber studies, which we can now provide to our clients all in one high quality service package.
Toronto, Ontario (PRWEB) June 02, 2015
Inflamax Research Inc., announced today that is has entered into a strategic alliance with Japan’s leading CRO, the InCROM Group, to bring Inflamax Research’s next generation Mobile Environmental Exposure Chamber (mEEC™) system to Japan. This strategic alliance will allow Japanese and non-Japanese clients access to world leading technology and expertise in developing new therapies for the treatment of allergic disease toward the Japanese market. Inflamax’s mEEC™ system will be the only mobile EEC system available in Japan for the conduct of multi-center EEC studies. Additionally, Inflamax’s mEEC™ system is validated for allergens not currently available in Japan such as house dust mite and cat, in addition to Japanese Cedar & Cypress, Birch and Oak Trees, Grass and Ragweed.
“We are very fortunate and excited to be working with such a world renowned CRO in Japan. This partnership will benefit both the companies tremendously. Inflamax’s world leading expertise in the conduct of EEC studies will be available for studies conducted in Japan with InCROM’s local expertise in recruitment and study conduct.” says Dr. Anne Marie Salapatek, President and CSO of Inflamax Research. “Inflamax has the largest EEC installation globally with experienced staff, who have conducted more EEC studies than any other CRO in the world. This unique experience, combined with scientific expertise and the world’s largest database of previous studies, provides our clients with un-paralleled confidence in the design and conduct of the most efficient EEC study -- both single center and now with Inflamax’s mEEC™s, the capability to conduct multi-center and multi-national EEC studies worldwide.”
The mEEC™ is a state of the art facility designed to expose patients to controlled levels of airborne allergen, similar to those experienced in their daily lives, while reducing the variability of results, and increasing patient compliance compared to typical field trials. The mEECTM was created to meet the regulatory need for geographic diversity across large multi-centre clinical trials that are suitable and required for late phase clinical research.
“We are very pleased to have a collaboration with Inflamax Research who has tremendous amount of experience and strong track record with successful Environmental Exposure Chamber studies, which we can now provide to our clients all in one high quality service package. The Environmental Exposure Chamber approach provides significant benefit to allergy trials, providing high quality clinical efficacy data outcomes and the ability to perform the trial at any time in the year, even off-season. We are proud to say that we can now offer our customers the mEEC™ study option in Japan.” says Mr. Matsushima, General Manager of Marketing Division InCROM.
About Inflamax Research Inc.
Inflamax Research Inc. is a full-service Clinical Research Organization (CRO) with clinical research facilities in both Canada (Mississauga) and the USA (New Jersey), specializing in allergy and asthma clinical research with over 25 years’ experience in the conduct of clinical trials and a recognized world leader in Environmental Exposure Chamber scientific expertise and technology. Inflamax is experienced in phase I clinical pharmacology through to late phase, global, and multi-center clinical research services, as well as post marketing studies.
About InCROM Group
InCROM Group is a full-service clinical research organisation and a pioneer of the Japanese clinical studies with 32 years of experience managing projects of all study phases and types with 1,276 protocols to date. InCROM has a lot of experience in the field of allergy, diabetes, hypertension, hyperlipidemia, dialysis and ophthalmic especially for allergic rhinitis. We have conducted 10 protocols with 2,652 patients enrolled within 5 years from 2010. InCROM’s strength is to conduct the study with highly experienced staff all within the InCROM Group.